Product menu

Picture of woman jogging
Your patients ≥50 years old are at risk for shingles, even if they have a healthy lifestyle¹

≥90% of Canadians have had varicella and are at risk for shingles2

Picture of woman jogging

Age-related decline in immunity was shown to be the dominant driver of shingles1

shingrix-unmet-need-age

Increasing age causes a natural decline in immunity.1 2/3 of shingles cases occur in those over the age of 50.3

shingrix-unmet-need-immunity

There is a reduction in the number and functionality of immune cells that prevent reactivation of the varicella zoster virus (VZV).1,4

shingrix-unmet-need-shingles

This leads to an increase in the incidence and severity of shingles.1

Do your patients 50 years and older know they are at risk?

≥90% of Canadians have had varicella (chickenpox) and are at risk for shingles.2

Approximately 1 out of 3 people will develop shingles during their lifetime, due to a reactivation of the dormant virus — a blistering rash that can be accompanied by burning, stabbing, or shock-like pain.1,5

Pictures of shingles rash on different parts of the body1
Pictures of shingles rash on different parts of the body2
Pictures of shingles rash on different parts of the body3

Shingles can lead to serious and long-lasting complications:1*

Postherpetic neuralgia (PHN)

  • Affects up to 30% of patients with shingles2
  • Characterized by long-lasting nerve pain that can persist for months to years1

Herpes zoster ophthalmicus

  • Affects up to 25% of patients with shingles1
  • Can lead to ophthalmic complications and, in rare cases, vision loss1,6

* SHINGRIX is not indicated for the prevention of primary varicella infection or for the treatment of HZ or PHN.7

What to share with your patients?

As you age, your immune system naturally declines, increasing your risk of shingles.1

Do your patients 50 years and older know they are at risk?

≥90% of Canadians have had varicella (chickenpox) and are at risk for shingles.2

Approximately 1 out of 3 people will develop shingles during their lifetime, due to a reactivation of the dormant virus – a blistering rash that can be accompanied by burning, stabbing or shock-like pain.1,5

Pictures of shingles rash on different parts of the body2
Pictures of shingles rash on different parts of the body3

Shingles can lead to serious and long-lasting complications1*:

Postherpetic neuralgia (PHN)

  • Affects up to 30% of patients with shingles2
  • Characterized by long-lasting nerve pain that can persist for months to years1

Herpes zoster ophthalmicus

  • Affects up to 25% of patients with shingles1
  • Can lead to ophthalmic complications and, in rare cases, vision loss1,6

* SHINGRIX is not indicated for the prevention of primary varicella infection or for the treatment of HZ or PHN.7

What to share with your patients?

As you age, your immune system naturally declines, increasing your risk of shingles.1

Learn more about the design of SHINGRIX

Discover the components and the mechanism of action of SHINGRIX.

90% Efficacy

The efficacy profile of SHINGRIX in adults ≥50 years was studied in two phase III trials with 29,305 patients

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70).7

Learn more
Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.8

Learn more
Checkmark icon

SHINGRIX: Recommendations from NACI and CIQ

Review the recommendations on the use of SHINGRIX by the National Advisory Committee on Immunization (NACI) and the Comité sur l’immunisation du Québec (CIQ).8,9

Learn more

References:

  1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.
  2. National Advisory Committee on Immunization (NACI). Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep 2010;36(ACS-1):1-19.
  3. Government of Canada. Canadian Immunization Guide: Part 4 – Active Vaccines. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed March 5, 2018.
  4. Weinberg A et al. Influence of age and nature of primary infection on varicella-zoster virus—specific cell-mediated immune responses. J Infect Dis 2010;201(7):1024-1030.
  5. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4(6):e004833.
  6. Volpi A. Severe complications of herpes zoster. Herpes 2007;14 Suppl 2:35-9.
  7. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  8. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  9. Reproduction of information from the PIQ, 7th ed. Zona-SU section. Available at: http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/. Accessed November 30, 2022.
    The original French version of this information was published in 2018 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.

Trademarks are owned by or licensed to the GSK group of companies.

©2022 GSK Group of Companies or its licensor.

10141 | 12/22